Loading organizations...
Addex Therapeutics is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, that discovers and develops small molecule allosteric modulators for central nervous system disorders. Operating as a publicly traded micro-cap biotech firm with fewer than 50 employees, the enterprise utilizes a proprietary technology platform to create targeted treatments for complex conditions such as Parkinson's disease, epilepsy, and substance use disorders. The business advances its clinical pipeline through strategic licensing agreements and research partnerships with major pharmaceutical entities, including Indivior and Janssen Pharmaceuticals, to fund ongoing trials and operations. In 2024, the organization partnered with investment firm Perceptive Advisors to launch Neurosterix, transferring its preclinical portfolio in exchange for CHF 5 million and a 20 percent equity stake in the new entity. Addex Therapeutics was originally founded in 2002 by co-founders Tim Dyer and Vincent Mutel.
Addex Therapeutics has raised $82.0M across 3 funding rounds.
Key people at Addex Therapeutics.
Addex Therapeutics has raised $82.0M in total across 3 funding rounds.
Addex Therapeutics has raised $82.0M across 3 funding rounds. Most recently, it raised $32.0M Series C in September 2006.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2006 | $32M Series C | — | Soffinova Partners | Announced |
| May 1, 2004 | $40M Series B | — | Soffinova Partners | Announced |
| Jul 1, 2002 | $10M Series A | — | Soffinova Partners | Announced |
Key people at Addex Therapeutics.
Addex Therapeutics has raised $82.0M in total across 3 funding rounds.
Addex Therapeutics's investors include Soffinova Partners.
Addex Therapeutics is a clinical-stage biopharmaceutical company developing novel small molecule allosteric modulators targeting neurological disorders.[1][2][3] Its lead candidate, dipraglurant (mGlu5 NAM), focuses on post-stroke and traumatic brain injury recovery, while other programs include ADX71149 (mGlu2 PAM), GABAB PAM for substance use disorder (partnered with Indivior), and GABAB PAM for chronic cough.[1][2][4] Addex serves patients with unmet needs in neurology, addressing problems like sensorimotor deficits post-stroke, addiction, and cough through orally available drugs that modulate receptor function more precisely than traditional orthosteric ligands.[2][3] Growth momentum includes Indivior's 2024 selection of a GABAB PAM for substance use disorder development and Addex's independent chronic cough program, alongside a 20% stake in Neurosterix advancing modulators for schizophrenia, mood disorders, and neurocognitive issues; however, 2024 saw reduced revenue to CHF 0.4 million and a net loss of CHF 4.9 million.[2][4]
Addex Therapeutics, listed on the SIX Swiss Exchange and NASDAQ Capital Market under ticker ADXN, emerged as a pioneer in allosteric modulation technology for neurological disorders, though specific founding year and founders are not detailed in available sources.[2][5] The company has evolved from early research into a clinical-stage entity with a portfolio of modulators, marked by pivotal partnerships like the funded collaboration with Indivior, which culminated in compound selection for substance use disorders in August 2024 after research completion in June 2024.[4] Key milestones include advancing dipraglurant for brain injury recovery and spinning out Neurosterix, building momentum through clinical progress and equity interests in 2024 despite financial challenges.[2][4]
Addex stands out in biopharma through its focus on allosteric modulators, which bind distinct receptor sites to fine-tune activity, offering potential advantages in efficacy and safety over conventional drugs:
Addex rides the trend of precision neurology therapeutics, where allosteric modulators enable subtype-selective targeting amid rising demand for treatments in stroke recovery (affecting millions annually), substance use disorders, and schizophrenia—markets bolstered by aging populations and post-pandemic mental health focus.[1][2] Timing aligns with advances in structural biology accelerating modulator discovery, while partnerships like Indivior's validate the approach amid Big Pharma's interest in de-risked assets.[4] Market forces favoring Addex include Switzerland's biotech hub status and NASDAQ/SIX listings aiding funding, influencing the ecosystem by advancing Neurosterix and proving allosteric tech's viability beyond orthosteric inhibitors.[2][5]
Addex's path forward hinges on dipraglurant advancement in brain injury, chronic cough GABAB PAM data, and Neurosterix milestones, potentially unlocking partnerships or milestones from Indivior.[2][4] Trends like AI-driven drug design and neurology investment surges could accelerate its modulators, evolving its role from developer to licensor with scaled equity plays. As a nimble clinical player navigating 2024 losses, success in de-risking assets positions Addex to deliver targeted therapies in a high-need field.[4]
